A new pilot program from HHS would alter the contentious 340B pricing program by swapping traditional upfront drug discounts for rebates.
Amy Baxter is a staff reporter for PharmaVoice. With a robust background in the B2B healthcare space, she has covered topics such as pharmaceutical manufacturing, regulation, and healthcare administration, drawing on her experience from previous roles at Health Exec and Home Health Care News. Amy's insights have also been featured in notable publications including Environmental Leader, BioPharma Dive, and Sailing World Inc.










